Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Capital Expenditures (2016 - 2025)

Conmed's Capital Expenditures history spans 16 years, with the latest figure at $5.1 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 26.51% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $19.8 million, up 51.38%, while the annual FY2025 figure was $19.8 million, 51.38% up from the prior year.
  • Capital Expenditures reached $5.1 million in Q4 2025 per CNMD's latest filing, down from $5.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $6.7 million in Q3 2022 to a low of $2.0 million in Q1 2024.
  • Average Capital Expenditures over 5 years is $4.4 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: surged 90.75% in 2022, then plummeted 52.16% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $3.2 million in 2021, then skyrocketed by 78.04% to $5.7 million in 2022, then decreased by 14.46% to $4.9 million in 2023, then dropped by 16.79% to $4.0 million in 2024, then increased by 26.51% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's Capital Expenditures are $5.1 million (Q4 2025), $5.2 million (Q3 2025), and $5.7 million (Q2 2025).